Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 85.00 [7][8] Core Views - Despite facing external factors in Q2 2025, the company achieved revenue and profit growth in H1 2025, demonstrating brand resilience and performance stability [1][7] - The upcoming Double 11 shopping festival is expected to boost sales through brand promotion and influencer marketing activities [1] - The company has recently acquired exclusive patents related to collagen and ginseng saponins, indicating ongoing innovation and potential for expanding the application of its premium raw materials [1][3] - The brand's sales on Douyin are anticipated to recover, aided by influencer promotions, with a notable live-streaming event generating over HKD 16 million in sales [2][3] Revenue and Profit Forecast - The company forecasts net profits for 2025, 2026, and 2027 to be RMB 2.6 billion, RMB 3.2 billion, and RMB 3.8 billion respectively, with corresponding EPS of RMB 2.53, RMB 3.11, and RMB 3.71 [5][10] - Revenue is projected to grow significantly, with estimates of RMB 7.1 billion in 2025, RMB 8.8 billion in 2026, and RMB 10.5 billion in 2027, reflecting growth rates of 28.45%, 23.37%, and 19.18% respectively [10][19] Market Expansion and Innovation - The company is actively exploring overseas markets, having successfully entered Malaysia and expanded into South Korea and France, which may provide new growth opportunities [4] - Recent patent approvals for innovative products indicate a strong focus on R&D and potential for future product launches [3][4] Sales Performance - The sales performance in July and August showed strong growth, with GMV for the brands reaching HKD 172 million and HKD 19 million respectively, marking year-on-year increases of 48% and 77% [2][3] - The company has been expanding its offline presence, with new store openings and product placements in key retail locations [3]
巨子生物（02367）：品牌定力与业绩韧性彰显，期待25H2增长提速